Search - tctmd.com

Displaying 201 - 220 of 361

Sort: Relevancy | Date

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

L.A. McKeown

August 27, 2022

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

Caitlin E. Cox

July 04, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News ESC Heart Failure 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Speech-Recognition Tool May Predict Worsening Congestion in HF

Shelley Wood

May 22, 2022

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

Shelley Wood

May 22, 2022

News Conference News EuroPCR 2022

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

Michael O'Riordan

May 20, 2022

News Conference News EuroPCR 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Michael O'Riordan

May 19, 2022

News Daily News

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

Michael O'Riordan

May 06, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

Advertisement

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

What’s Going to Be Hot at ESC 2022?

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

TCTMD’s Top 10 Most Popular Stories for June 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Dapagliflozin Boosts Health Status Across LVEF Range

Speech-Recognition Tool May Predict Worsening Congestion in HF

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content